GHR Foundation, a hope-fueled global funder of service to people and their limitless potential for good, completed the $15m investment in C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company. “As a hope-fueled global funder in service to people and their limitless potential for good, GHR Foundation is honored to partner with the C₂N Diagnostics team and bolster the difference they’re making in the lives of patients and families dealing with the uncertainty of an Alzheimer’s diagnosis,” Amy Rauenhorst Goldman, GHR Foundation CEO and Chair.